Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGI-2001 for aGvHD Prevention
NCT04014790Phase 2Completed
- Sponsor
- REGiMMUNE
- Start
- Nov 2019
- Primary completion
- Jul 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of RGI-2001 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by REGiMMUNE. Started Nov 2019; status: completed.
02
Drugs
RGI-2001
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04014790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014790.